GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Scaled Net Operating Assets

CLGN (CollPlant Biotechnologies) Scaled Net Operating Assets : 0.18 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CollPlant Biotechnologies's operating assets for the quarter that ended in Sep. 2024 was $7.07 Mil. CollPlant Biotechnologies's operating liabilities for the quarter that ended in Sep. 2024 was $2.27 Mil. CollPlant Biotechnologies's Total Assets for the quarter that ended in Jun. 2024 was $26.57 Mil. Therefore, CollPlant Biotechnologies's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.18.


CollPlant Biotechnologies Scaled Net Operating Assets Historical Data

The historical data trend for CollPlant Biotechnologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Scaled Net Operating Assets Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.42 0.50 0.11 0.13

CollPlant Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.13 0.12 0.17 0.18

Competitive Comparison of CollPlant Biotechnologies's Scaled Net Operating Assets

For the Biotechnology subindustry, CollPlant Biotechnologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Scaled Net Operating Assets falls into.



CollPlant Biotechnologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CollPlant Biotechnologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(7.452-2.627)/37.768
=0.13

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=34.126 - 26.674
=7.452

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=5.786 - 2.535 - 0.624
=2.627

CollPlant Biotechnologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(7.071-2.271)/26.566
=0.18

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=22.442 - 15.371
=7.071

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=5.524 - 2.455 - 0.798
=2.271

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CollPlant Biotechnologies Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.